Eli Lilly and Company announced third-quarter financial results that significantly surpassed Wall Street expectations, driven by surging demand for its weight-loss and diabetes drugs, Mounjaro and Zepbound. The company reported a 54% increase in revenue to $17.6 billion and adjusted earnings of $7.02 per share, well above analysts' forecasts. Following the strong quarterly performance, Eli Lilly raised its full-year 2025 guidance. The company now projects revenue to be between $63.0 billion and $63.5 billion, with adjusted earnings per share expected in the range of $23.00 to $23.70. The updated forecast reflects confidence in the sustained momentum of its key products and strong underlying business performance. The market reacted positively to the news. The company's shares rose nearly 2% in morning trading following the announcement, as investors showed confidence in the company's accelerating growth across its portfolio.